<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200781</url>
  </required_header>
  <id_info>
    <org_study_id>19401972800</org_study_id>
    <nct_id>NCT04200781</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke</brief_title>
  <official_title>A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ShuGuang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Shengdi Dahuang Decoction
      in the treatment of acute hemorrhagic stroke by the randomized, controlled, double-blind,
      multi-center trial design project.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of the study is to observe the clinical efficacy and safety of Shengdi
      Dahuang Decoction in the treatment of acute hemorrhagic stroke. This project is funded by
      Science and Technology Commission of Shanghai Municipality and will be carried out in 5
      hospitals. Investigators will recruit 464 participants who meet the inclusion criteria and
      agree to participate in the research. Participants will be randomly assigned into
      experimental or placebo group. Granules of Shengdi Decoction is the therapeutic drug used in
      the experimental group. Each pack of the test drug contains 15 grams of rehmannia and 5 grams
      of rhubarb. While for the placebo group, each pack contains 2% rehmannia and rhubarb.
      Participants will receive a follow-up observation in the following 90 days. Modified Rankin
      Scale score (mRS), the mortality rate on day 7 and day 90 after treatment, National Institute
      of Health Stroke Scale (NIHSS), expansion rate of hematoma, the degree of edema and the
      expressions of inflammatory indicators will be detected to evaluate the clinical efficacy of
      Shengdi Dahuang Decoction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disability rate</measure>
    <time_frame>90 days</time_frame>
    <description>Modified Rankin Scale score (mRS) will be graded on the 90th day after onset (mRS score ranges from 0 point (no symptoms at all) to 5 points (severe disability)).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate on the 7th day</measure>
    <time_frame>7 days</time_frame>
    <description>The proportion of deaths (mortality rate, %) in different groups on 7th day after treatment will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate on the 90th day</measure>
    <time_frame>90 days</time_frame>
    <description>The proportion of deaths (mortality rate, %) in different groups on 90th day after treatment will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of neurological deficit</measure>
    <time_frame>7 days</time_frame>
    <description>National Institute of Health Stroke Scale (NIHSS) will be used to assess the severity of neurological deficit on the 7th day after treatment. NIHSS score ranges from 0 point to 42 points. More severe neurological deficit could be observed in participants with the higher score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of hematoma enlargement cases</measure>
    <time_frame>24 hours</time_frame>
    <description>All participants will reexamine the skull CT scan 24 hours after onset. The volume of hematoma (ml) increases more than 6ml or 33% relative increment than original volume is defined as the expansion of hematoma. The proportion of hematoma enlargement cases (%) will be compared between different groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of edema</measure>
    <time_frame>7 days</time_frame>
    <description>All participants will reexamine the skull CT scan on the 7th day after treatment. The volume (ml) of edema and hematoma will be calculated respectively. The ratio of edema volume and hematoma volume represents the severity of edema.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">464</enrollment>
  <condition>Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>Shengdi Dahuang Decoction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To clarify the clinical effects of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke and to explore the possible mechanism. Participants will take the granules of Shengdi Dahuang Decoction that contains 15 grams of rehmannia and 5 grams of rhubarb, one pack per time, twice a day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To explore the effective clinical therapy in acute hemorrhagic stroke. Participants will take placebo contains 2% rehmannia and rhubarb, one pack per time, twice a day for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granules of Shengdi Dahuang Decoction</intervention_name>
    <description>Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.</description>
    <arm_group_label>Shengdi Dahuang Decoction</arm_group_label>
    <other_name>Chinese Herbal Compound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo granules has the same appearence, weight, shape and color as the experimental drug.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo of Chinese Herbal Compound</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet the diagnostic criteria of acute intracerebral hemorrhage；

          2. CT scan reveals cerebral parenchymal hemorrhage and the volume of hematoma is &lt;80ml;

          3. The time from onset to confirmed diagnosis by CT scan is within 4 hours;

          4. Enrolled and receive treatment within 12 hours from onset;

          5. Age ≥18 years old;

          6. Obtain approval from the patient or family members.

        Exclusion Criteria:

          1. The time from onset to confirmed diagnosis by CT scan is over 4 hours;

          2. CT scan indicate that the sites of hemorrhage are in the cerebellum, brainstem and
             ventricle (note: in case of cerebral parenchymal hemorrhage combined with ventricular
             hemorrhage, patients will be excluded if the volume of ventricular hemorrhage is the
             larger one);

          3. The volume of hematoma is above 80ml;

          4. Glasgow Coma Scale (GCS) is ≤ 5 points;

          5. The time from onset to confirmed diagnosis is over 12 hours;

          6. Have a surgical treatment planning within 24 hours;

          7. Cerebral hemorrhage caused by trauma, arteriovenous malformation, thrombolytic
             therapy, anticoagulant therapy or other reasons;

          8. Patients with disabilities before onset (modified mRS score &gt; 2);

          9. Patients with severe primary diseases of the heart, lung, liver, kidney, endocrine
             systems or hematopoietic system;

         10. Patients who have participated in other clinical trials within the past 1 month;

         11. Pregnant or nursing women;

         12. Allergic constitution (allergic to more than two kinds of food or medications).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofei Yu</last_name>
    <role>Study Chair</role>
    <affiliation>Shuguang Hospital affiliated with Shanghai University of TCM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoyu Yu</last_name>
    <phone>86-021-20256378</phone>
    <email>doctorxiaoyu@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai seventh People's Hospital, Seventh People's Hospital of Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wang</last_name>
      <phone>+86-13816566556</phone>
      <email>13816566556@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingyan Xiang</last_name>
      <phone>86-18930173850</phone>
      <email>xiang_jing_yan@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyu Zhou</last_name>
      <phone>86-18049929570</phone>
      <email>13564532819@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shuguang Hospital affiliated with Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofei Yu</last_name>
      <phone>86-13331978806</phone>
      <email>doctorxiaoyu@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Han</last_name>
      <phone>86-13917022800</phone>
      <email>hanyan.2006@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Arima H, Heeley E, Delcourt C, Hirakawa Y, Wang X, Woodward M, Robinson T, Stapf C, Parsons M, Lavados PM, Huang Y, Wang J, Chalmers J, Anderson CS; INTERACT2 Investigators; INTERACT2 Investigators. Optimal achieved blood pressure in acute intracerebral hemorrhage: INTERACT2. Neurology. 2015 Feb 3;84(5):464-71. doi: 10.1212/WNL.0000000000001205. Epub 2014 Dec 31.</citation>
    <PMID>25552575</PMID>
  </results_reference>
  <results_reference>
    <citation>Cai M, Yu Z, Zhang W, Yang L, Xiang J, Zhang J, Zhang Z, Wu T, Li X, Fu M, Bao X, Yu X, Cai D. Sheng-Di-Da-Huang Decoction Inhibited Inflammation Expressed in Microglia after Intracerebral Hemorrhage in Rats. Evid Based Complement Alternat Med. 2018 Oct 18;2018:6470534. doi: 10.1155/2018/6470534. eCollection 2018.</citation>
    <PMID>30498516</PMID>
  </results_reference>
  <results_reference>
    <citation>Chang JJ, Emanuel BA, Mack WJ, Tsivgoulis G, Alexandrov AV. Matrix metalloproteinase-9: dual role and temporal profile in intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2498-505. doi: 10.1016/j.jstrokecerebrovasdis.2014.07.005. Epub 2014 Oct 11. Review.</citation>
    <PMID>25306400</PMID>
  </results_reference>
  <results_reference>
    <citation>Behrouz R, Azarpazhooh MR, Godoy DA, Hoffmann MW, Masotti L, Parry-Jones AR, Popa-Wagner A, Schreuder FH, Slevin MA, Smith CJ, Di Napoli M; MNEMONICH Steering Committee. The Multi-National survey on Epidemiology, Morbidity, and Outcomes iN Intracerebral Haemorrhage (MNEMONICH). Int J Stroke. 2015 Dec;10(8):E86. doi: 10.1111/ijs.12629.</citation>
    <PMID>26745705</PMID>
  </results_reference>
  <results_reference>
    <citation>Cordonnier C, Demchuk A, Ziai W, Anderson CS. Intracerebral haemorrhage: current approaches to acute management. Lancet. 2018 Oct 6;392(10154):1257-1268. doi: 10.1016/S0140-6736(18)31878-6. Review. Erratum in: Lancet. 2019 Feb 2;393(10170):406.</citation>
    <PMID>30319113</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding R, Chen Y, Yang S, Deng X, Fu Z, Feng L, Cai Y, Du M, Zhou Y, Tang Y. Blood-brain barrier disruption induced by hemoglobin in vivo: Involvement of up-regulation of nitric oxide synthase and peroxynitrite formation. Brain Res. 2014 Jul 7;1571:25-38. doi: 10.1016/j.brainres.2014.04.042. Epub 2014 May 9.</citation>
    <PMID>24814387</PMID>
  </results_reference>
  <results_reference>
    <citation>Flower O, Smith M. The acute management of intracerebral hemorrhage. Curr Opin Crit Care. 2011 Apr;17(2):106-14. doi: 10.1097/MCC.0b013e328342f823. Review.</citation>
    <PMID>21169826</PMID>
  </results_reference>
  <results_reference>
    <citation>Garg R, Biller J. Recent advances in spontaneous intracerebral hemorrhage. F1000Res. 2019 Mar 18;8. pii: F1000 Faculty Rev-302. doi: 10.12688/f1000research.16357.1. eCollection 2019. Review.</citation>
    <PMID>30906532</PMID>
  </results_reference>
  <results_reference>
    <citation>Geng X, Ren C, Wang T, Fu P, Luo Y, Liu X, Yan F, Ling F, Jia J, Du H, Ji X, Ding Y. Effect of remote ischemic postconditioning on an intracerebral hemorrhage stroke model in rats. Neurol Res. 2012 Mar;34(2):143-8. doi: 10.1179/1743132811Y.0000000073. Epub 2012 Jan 13.</citation>
    <PMID>22333136</PMID>
  </results_reference>
  <results_reference>
    <citation>Gregson BA, Mitchell P, Mendelow AD. Surgical Decision Making in Brain Hemorrhage. Stroke. 2019 May;50(5):1108-1115. doi: 10.1161/STROKEAHA.118.022694.</citation>
    <PMID>30932784</PMID>
  </results_reference>
  <results_reference>
    <citation>Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, Dawson J, Gandhi D, Ullman N, Mould WA, Mayo SW, Mendelow AD, Gregson B, Butcher K, Vespa P, Wright DW, Kase CS, Carhuapoma JR, Keyl PM, Diener-West M, Muschelli J, Betz JF, Thompson CB, Sugar EA, Yenokyan G, Janis S, John S, Harnof S, Lopez GA, Aldrich EF, Harrigan MR, Ansari S, Jallo J, Caron JL, LeDoux D, Adeoye O, Zuccarello M, Adams HP Jr, Rosenblum M, Thompson RE, Awad IA; CLEAR III Investigators. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017 Feb 11;389(10069):603-611. doi: 10.1016/S0140-6736(16)32410-2. Epub 2017 Jan 10.</citation>
    <PMID>28081952</PMID>
  </results_reference>
  <results_reference>
    <citation>Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo SW, Bistran-Hall AJ, Gandhi D, Mould WA, Ullman N, Ali H, Carhuapoma JR, Kase CS, Lees KR, Dawson J, Wilson A, Betz JF, Sugar EA, Hao Y, Avadhani R, Caron JL, Harrigan MR, Carlson AP, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine MR, Patel H, Dodd R, Camarata PJ, Wolfe S, Stadnik A, Money PL, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum JS, Wang W, Anderson CS, Mendelow AD, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad IA; MISTIE III Investigators. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019 Mar 9;393(10175):1021-1032. doi: 10.1016/S0140-6736(19)30195-3. Epub 2019 Feb 7. Erratum in: Lancet. 2019 Apr 20;393(10181):1596.</citation>
    <PMID>30739747</PMID>
  </results_reference>
  <results_reference>
    <citation>Hao S, Wang B. Editorial: Review on Intracerebral Haemorrhage: Multidisciplinary Approaches to the Injury Mechanism Analysis and Therapeutic Strategies. Curr Pharm Des. 2017;23(15):2159-2160. doi: 10.2174/1381612823999170307150448.</citation>
    <PMID>28703081</PMID>
  </results_reference>
  <results_reference>
    <citation>Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008 May 15;358(20):2127-37. doi: 10.1056/NEJMoa0707534.</citation>
    <PMID>18480205</PMID>
  </results_reference>
  <results_reference>
    <citation>Morotti A, Brouwers HB, Romero JM, Jessel MJ, Vashkevich A, Schwab K, Afzal MR, Cassarly C, Greenberg SM, Martin RH, Qureshi AI, Rosand J, Goldstein JN; Antihypertensive Treatment of Acute Cerebral Hemorrhage II and Neurological Emergencies Treatment Trials Investigators. Intensive Blood Pressure Reduction and Spot Sign in Intracerebral Hemorrhage: A Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. 2017 Aug 1;74(8):950-960. doi: 10.1001/jamaneurol.2017.1014.</citation>
    <PMID>28628707</PMID>
  </results_reference>
  <results_reference>
    <citation>Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol. 2009 Jun;9(6):429-39. doi: 10.1038/nri2565. Review.</citation>
    <PMID>19461673</PMID>
  </results_reference>
  <results_reference>
    <citation>Selim M, Sheth KN. Perihematoma edema: a potential translational target in intracerebral hemorrhage? Transl Stroke Res. 2015 Apr;6(2):104-6. doi: 10.1007/s12975-015-0389-7. Epub 2015 Feb 20.</citation>
    <PMID>25693976</PMID>
  </results_reference>
  <results_reference>
    <citation>Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, Bath PM; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018 May 26;391(10135):2107-2115. doi: 10.1016/S0140-6736(18)31033-X. Epub 2018 May 16.</citation>
    <PMID>29778325</PMID>
  </results_reference>
  <results_reference>
    <citation>Toyoda K, Grotta JC. Seeking best medical treatment for hyperacute intracerebral hemorrhage. Neurology. 2015 Feb 3;84(5):444-5. doi: 10.1212/WNL.0000000000001221. Epub 2014 Dec 31.</citation>
    <PMID>25552577</PMID>
  </results_reference>
  <results_reference>
    <citation>van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010 Feb;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0. Epub 2010 Jan 5. Review.</citation>
    <PMID>20056489</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol. 2010 Dec;92(4):463-77. doi: 10.1016/j.pneurobio.2010.08.001. Epub 2010 Aug 14. Review.</citation>
    <PMID>20713126</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ShuGuang Hospital</investigator_affiliation>
    <investigator_full_name>Xiaofei Yu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>acute hemorrhagic stroke</keyword>
  <keyword>Shengdi Dahuang Decoction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

